# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Piper Sandler analyst Matt O'Brien downgrades AVITA Medical (NASDAQ:RCEL) from Overweight to Neutral and lowers the pric...
Cantor Fitzgerald analyst Ross Osborn maintains AVITA Medical (NASDAQ:RCEL) with a Overweight and lowers the price target fr...
Financial GuidanceCommercial revenue for the second quarter 2024 is expected to be in the range of $14.3 to $15.3 millionCommer...
AVITA Medical (NASDAQ:RCEL) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.4...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The D...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Thursday.